Tat transactivation: A model for the regulation of eukaryotic transcriptional elongation

Virology

Volumn 264, Issue 2, 1999, Pages 245-253

  Taube, Ran ^a   Fujinaga, Koh ^a   Wimmer, Joerg ^a   Barboric, Matjaz ^a   Peterlin, B Matija ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL SEQUENCE; EUKARYOTE; EXON; GENE EXPRESSION; GENE REPLICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; LIFE CYCLE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSACTIVATION; VIRUS GENE;

EID: 0033604520     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9944     Document Type: Article

References (112)

1. Adams M., Sharmeen L., Kimpton J., Romeo J. M., Garcia J. V., Peterlin B. M., Groudine M., Emerman M. Cellular latency in human immunodeficiency virus-infected individuals. Proc. Natl. Acad. Sci. USA. 91:1994;3862-3866.
2. Alonso A., Cujec T. P., Peterlin B. M. Effects of human chromosome 12 on interactions between Tat and TAR of human immunodeficiency virus type 1. J. Virol. 68:1994;6505-6513.
3. Alonso A., Derse D., Peterlin B. M. Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells. J. Virol. 66:1992;4617-4621.
4. Andersen G., Busso D., Poterszman A., Hwang J. R., Wurtz J. M., Ripp R., Thierry J. C., Egly J. M., Moras D. The structure of cyclin H: common mode of kinase activation and specific features. EMBO J. 16:1997;958-967.
5. Benkirane M., Chun R. F., Xiao H., Ogryzko V. V., Howard B. H., Nakatani Y., Jeang K. T. Activation of integrated provirus requires histone acetyltransferase: p300 and P/CAF are coactivators for HIV-1 Tat. J. Biol. Chem. 273:1998;24898-28905.
6. Benko D. M., Schwartz S., Pavlakis G. N., Felber B. K. A novel human immunodeficiency virus type 1 protein, tev, shares sequences with tat, env, and rev proteins. J. Virol. 64:1990;2505-2518.
7. Berkhout B., Gatignol A., Rabson A. B., Jeang K. T. TAR-independent activation of the HIV-1 LTR: Evidence that tat requires specific regions of the promoter. Cell. 62:1990;757-767.
8. Bieniasz P. D., Grdina T. A., Bogerd H. P., Cullen B. R. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 17:1998;7056-7065.
9. Bieniasz P. D., Grdina T. A., Bogerd H. P., Cullen B. R. Analysis of the effect of natural sequence variation in tat and in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclinT complexes. J. Virol. 73:1999a;5777-5786.
10. Bieniasz P. D., Grdina T. A., Bogerd H. P., Cullen B. R. Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. Mol. Cell. Biol. 19:1999b;4592-4599.
11. Bieniasz P. D., Grdina T. A., Bogerd H. P., Cullen B. R. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc. Natl. Acad. Sci. USA. 96:1999c;7791-7796.
12. Blau J., Xiao H., McCracken S., O'Hare P., Greenblatt J., Bentley D. Three functional classes of transcriptional activation domains. Mol. Cell. Biol. 16:1996;2044-2055.
13. Bohjanen P. R., Liu Y., Garcia-Blanco M. A. TAR RNA decoys inhibit tat-activated HIV-1 transcription. Nucleic Acids Res. 25:1997;4481-4486.
14. Calnan B. J., Biancalana S., Hudson D., Frankel A. D. Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual features of RNA-protein recognition. Genes Dev. 5:1991;201-210.
15. Carroll R., Peterlin B. M., Derse D. Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans-activators. J. Virol. 66:1992;2000-2007.
16. Chen L., Frankel A. D. An RNA-binding peptide from bovine immunodeficiency virus Tat protein. Biochemistry. 33:1994;2708-2715.
17. Churcher M. J., Lamont C., Hamy F., Dingwall C., Green S. M., Lowe A. D., Butler J. G., Gait M. J., Karn J. High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region. J. Mol. Biol. 230:1993;90-110.
18. Cujec T. P., Cho H., Maldonado E., Meyer J., Reinberg D., Peterlin B. M. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol. Cell. Biol. 17:1997a;1817-1823.
19. Cujec. T. P., Fujinaga K., Meyer J., Chamberlin H., Morgan D., Peterlin B. M. The HIV transactivator Tat binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev. 11:1997b;1-12.
20. Cullen B. HIV-1 auxilary proteins: Making connections in a dying cell. Cell. 93:1998;685-692.
21. Dahmus M. E. Reversible phosphorylation of the C-terminal domain of RNA polymerase. J. Biol. Chem. 271:1996;19009-19012.
22. Dayton A. I., Sodroski J. G., Rosen C. A., Goh W. C., Haseltine W. A. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell. 44:1986;941-947.
23. Derse, D, Carroll, R, Cavalho, M, DaSilva, L, Martarano, L. 1991, Functional topography of lentivirus Tat proteins defined by domain switching. In, Genetic Structure and Regulation of HIV, (, W. A. Haseltine and F. Wong-Staal, Eds.), Raven Press, New York, 1991.
24. Derse D., Carvalho M., Carroll R., Peterlin B. M. A minimal lentivirus Tat. J. Virol. 65:1991;7012-7015.
25. Dingwall C., Ernberg I., Gait M. J., Green S. M., Heaphy S., Karn J., Lowe A. D., Singh M., Skinner M. A., Valerio R. Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc. Natl. Acad. Sci. USA. 86:1989;6925-6929.
26. Emerman M., Guyader M., Montagnier L., Baltimore D., Muesing M. A. The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1. EMBO J. 6:1987;3755-3760.
27. Emerman M., Malim M. H. HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology. Science. 280:1998;1880-1884.
28. Feinberg M. B., Baltimore D., Frankel A. D. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc. Natl. Acad. Sci. USA. 88:1991;4045-4049.
29. Feng S., Holland E. C. HIV-1 Tat transactivation requires the loop sequences within TAR. Nature. 249:1988;165-167.
30. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:1999;512-517.
31. Fisher A. G., Feinberg M. B., Josephs S. F., Harper M. E., Marselle L. M., Reyes G., Gonda M. A., Aldovini A., Debouk C., Gallo R. C. The trans-activator gene of HTLV-III is essential for virus replication. Nature. 320:1986;367-371.
32. Frankel A. D. Activation of HIV transcription by Tat. Curr. Opin. Genet. Dev. 2:1992a;293-298.
33. Frankel A. D. Peptide models of the Tat-TAR protein-RNA interaction. Prot. Sci. 1:1992b;1539-1542.
34. Frankel A. D., Kim P. S. Modular structure of transcription factors: Implications for gene regulation. Cell. 65:1991;717-719.
35. Frankel A. D., Young J. A. HIV-1: Fifteen proteins and an RNA. Annu. Rev. Biochem. 67:1998;1-25.
36. Fujinaga K., Cujec T. P., Peng J., Garriga J., Price D. H., Grana X., Peterlin B. M. The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J. Virol. 72:1998;7154-7159.
37. Fujinaga K., Taube R., Wimmer J., Cujec T. P., Peterlin B. M. Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc. Natl. Acad. Sci. USA. 96:1999;1285-1290.
38. Gait M. J., Karn J. RNA recognition by the human immunodeficiency virus Tat and Rev proteins. Trends Biochem. Sci. 18:1993;255-259.
39. Gait M. J., Karn J. Progress in anti-HIV structure-based drug design. Trends Biotechnol. 13:1995;430-438.
40. Garber M. E., Wei P., KewalRamani V. N., Mayall T. P., Herrmann C. H., Rice A. P., Littman D. R., Jones K. A. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12:1998;3512-3527.
41. Garcia J. A., Harrich D., Pearson L., Mitsuyasu R., Gaynor R. B. Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J. 7:1988;3143-3147.
42. Garcia-Martinez L. F., Mavankal G., Neveu J. M., Lane W. S., Ivanov D., Gaynor R. B. Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J. 16:1997;2836-2850.
43. Garcia-Martinez L. F., Mavankal G., Peters P., Wu-Baer F., Gaynor R. B. Tat functions to stimulate the elongation properties of transcription complexes paused by the duplicated TAR RNA element of human immunodeficiency virus 2. J. Mol. Biol. 254:1995;350-363.
44. Gaynor R. B. Regulation of HIV-1 gene expression by the transactivator protein Tat. Curr. Top. Microbiol. Immunol. 193:1995;51-77.
45. Gilmour D. S., Lis J. T. In vivo interactions of RNA polymerase II with genes of Drosophila melanogaster. Mol. Cell. Biol. 5:1985;2009-2018.
46. Greenblatt J., Nodwell J. R., Mason S. W. Transcriptional antitermination. Nature. 364:1993;401-406.
47. Gold M. O., Yang X., Herrmann C. H., Rice A. P. PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo. J. Virol. 72:1998;4448-4453.
48. Hampsey M., Reinberg D. RNA polymerase II as a control panel for multiple coactivator complexes. Curr. Opin. Genet. Dev. 9:1999;132-139.
49. Hart C. E., Galphin J. C., Westhafer M. A., Schochetman G. TAR loop-dependent human immunodeficiency virus trans activation requires factors encoded on human chromosome 12. J. Virol. 67:1993;5020-5024.
50. Hart C. E., Westhafer M. A., Galphin J. C., Ou C. Y., Bacheler L. T., Petteway S. Jr., Wasmuth J. J., Chen I. S., Schochetman G. Human chromosome-dependent and -independent pathways for HIV-2 trans-activation. AIDS Res. Hum. Retroviruses. 7:1991;877-882.
51. Hauber J., Malim M. H., Cullen B. R. Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J. Virol. 63:1989;1181-1187.
52. Herrmann C., Rice A. Specific interactions of the human immunodeficiency virus Tat proteins with a cellular protein kinase. Virology. 197:1993;601-608.
53. Herrmann C. H., Gold M. O., Rice A. P. Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C-terminal domain. Nucleic Acids Res. 24:1996;501-508.
54. Herrmann C. H., Rice A. P. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: Candidate for a Tat cofactor. J. Virol. 69:1995;1612-1620.
55. Hottiger M. O., Nabel G. J. Interaction of human immunodeficiency virus type 1 Tat with the transcriptiona coactivators p300 and CREB binding protein. J. Virol. 72:1998;8252-8256.
56. Ivanov D., Kwak Y. T., Nee E., Guo J., Garcia-Martinez L. F., Gaynor R. B. Cyclin T1 domains involved in complex formation with Tat and TAR RNA. J. Mol. Biol. 288:1999;41-56.
57. Jeang K. T. Tat, Tat-associated kinase, and transcription. J. Biomed. Sci. 5:1998;24-27.
58. Jeffrey P. D., Russo A. A., Polyak K., Gibbs E., Hurwitz J., Massague J., Pavletich N. P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2. Nature. 376:1995;313-320.
59. Jiang Y. W., Veschambre P., Erdjument-Bromage H., Tempst P., Conaway J. W., Conaway R. C., Kornberg R. D. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc. Natl. Acad. Sci. USA. 95:1998;8538-8543.
60. Jones K. A. Taking a new TAK on Tat transactivation. Genes Dev. 11:1997;2593-2599.
61. Jones K. A., Peterlin B. M. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:1994;717-743.
62. Kamine J., Subramanian T., Chinnadurai G. Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein. Proc. Natl. Acad. Sci. USA. 88:1991;8510-8514.
63. Kao S. Y., Calman A. F., Luciw P. A., Peterlin B. M. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature. 330:1987;489-493.
64. Kwak Y. T., Ivanov D., Guo J., Nee E., Gaynor R. B. Role of the human and murine cyclin T proteins in regulating HIV-1 tat. J. Mol. Biol. 288:1999;57-69.
65. Laspia M. F., Rice A. P., Mathews M. B. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell. 59:1989;283-292.
66. Lee S. W., Gallardo H. F., Gaspar O., Smith C., Gilboa E. Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther. 2:1995;377-384.
67. Lis J., Wu C. Protein traffic on the heat shock promoter: Parking, stalling, and trucking along. Cell. 74:1993;1-4.
68. Luo Y., Madore S. J., Parslow T. G., Cullen B. R., Peterlin B. M. Functional analysis of interactions between Tat and the trans. J. Virol. 67:1993;5617-5622.
69. Madore S. J., Cullen B. R. Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function. J. Virol. 67:1993;3703-3711.
70. Madore S. J., Cullen B. R. Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators. Virology. 206:1995;1150-1154.
71. Mancebo H. S., Lee G., Flygare J., Tomassini J., Luu P., Zhu Y., Peng J., Blau C., Hazuda D., Price D., Flores O. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 11:1997;2633-2644.
72. Marciniak R. A., Calnan B. J., Frankel A. D., Sharp P. A. HIV-1 Tat protein trans-activates transcription in vitro. Cell. 63:1990;791-802.
73. Marzio G., Tyagi M., Gutierrez M. I., Giacca M. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc. Natl. Acad. Sci. USA. 95:1998;13519-13524.
74. Morgan D. O. Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu. Rev. Cell. Dev. Biol. 13:1997;261-291.
75. Okamoto H., Sheline C. T., Corden J. L., Jones K. A., Peterlin B. M. Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II. Proc. Natl. Acad. Sci. USA. 93:1996;11575-11579.
76. Orphanides G., Lagrange T., Reinberg D. The general transcription factors of RNA polymerase II. Genes Dev. 10:1996;2657-2683.
77. Otero G., Fellows J., Li Y., de Bizemont T., Dirac A. M., Gustafsson C. M., Erdjument-Bromage H., Tempst P., Svejstrup J. Q. Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation. Mol. Cell. 3:1999;109-118.
78. Palangat M., Meier T. I., Keene R. G., Landick R. Transcriptional pausing at +62 of the HIV-1 nascent RNA modulates. Mol. Cell. 1:1998;1033-1042.
79. Pallansch L. A., Lackman-Smith C. S., Gonda M. A. Bovine immunodeficiency-like virus encodes factors which trans activate. J. Virol. 66:1992;2647-2652.
80. Parada C. A., Roeder R. G. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature. 384:1996;375-378.
81. Peng J., Zhu Y., Milton J. T., Price D. H. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 12:1998;755-762.
82. Pessler F., Hernandez N. The HIV-1 inducer of short transcripts activates the synthesis of 5,6-dichloro-1-beta-d-benzimidazole-resistant short transcripts in vitro. J. Biol. Chem. 273:1998;5375-5384.
83. Puglisi J. D., Chen L., Frankel A. D., Williamson J. R. Role of RNA structure in arginine recognition of TAR RNA. Proc. Natl. Acad. Sci. USA. 90:1993;3680-3684.
84. Puglisi J. D., Tan R., Calnan B. J., Frankel A. D., Williamson J. R. Conformation of the TAR RNA-arginine complex by NMR spectroscopy. Science. 257:1992;76-80.
85. Reines D., Conaway J. W., Conaway R. C. The RNA polymerase II general elongation factors. Trends Biochem. Sci. 21:1996;351-355.
86. Rice A. P., Carlotti F. Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein. J. Virol. 64:1990;1864-1868.
87. Roy S., Delling U., Chen C. H., Rosen C. A., Sonenberg N. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat- mediated trans-activation. Genes Dev. 4:1990a;1365-1373.
88. Roy S., Parkin N. T., Rosen C., Itovitch J., Sonenberg N. Structural requirements for trans activation of human immunodeficiency virus type 1 long terminal repeat-directed gene expression by tat: Importance of base pairing, loop sequence, and bulges in the tat-responsive sequence. J. Virol. 64:1990b;1402-1406.
89. Ruben S., Perkins A., Purcell R., Joung K., Sia R., Burghoff R., Haseltine W. A., Rosen C. A. Structural and functional characterization of human immunodeficiency virus tat protein. J. Virol. 63:1989;1-8.
90. Selby M. J., Bain E. S., Luciw P. A., Peterlin B. M. Structure, sequence, and position of the stem-loop in TAR determine transcriptional elongation by Tat through the HIV-1 long terminal repeat. Genes Dev. 3:1989;547-558.
91. Selby M. J., Peterlin B. M. Trans-activation by HIV-1 Tat via a heterologous RNA binding protein. Cell. 62:1990;769-776.
92. Sheridan P. L., Mayall T. P., Verdin E., Jones K. A. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev. 11:1997;3327-3340.
93. Shilatifard A., Conaway J. W., Conaway R. C. Mechanism and regulation of transcriptional elongation and termination by RNA polymerase II. Curr. Opin. Genet. Dev. 7:1997;199-204.
94. Siomi H., Shida H., Maki M., Hatanaka M. Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J. Virol. 64:1990;1803-1807.
95. Southgate C., Zapp M. L., Green M. R. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein. Nature. 345:1990;640-642.
96. Southgate C. D., Green M. R. The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function. Genes Dev. 5:1991;2496-2507.
97. Svejstrup J. Q., Vichi P., Egly J. M. The multiple roles of transcription/repair factor TFIIH. Trends Biochem. Sci. 21:1996;346-350.
98. Tao J., Frankel A. D. Specific binding of arginine to TAR RNA. Proc. Natl. Acad. Sci. USA. 89:1992;2723-2726.
99. Taube R., Fujinaga K., Irwin D., Wimmer J., Peterlin B. M. Interactions between equine cyclin T, eTat, and the transactivation response element (TAR) are disrupted by a leucine to valine substitution found in human cyclin T. J. Virol. 1999.
100. Tiley L. S., Madore S. J., Malim M. M., Cullen B. R. The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. Genes Dev. 6:1992;2077-2087.
101. Wada T., Takagi T., Yamaguchi Y., Watanabe D., Handa H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro. EMBO J. 17:1998;7395-7403.
102. Weeks K. M., Ampe C., Schltz S. C., Steitz T. A., Crothers D. M. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science. 249:1990;1281-1285.
103. Weeks K. M., Crothers D. M. RNA recognition by Tat-derived peptides: Interaction in the major. Cell. 66:1991;577-588.
104. Wei P., Garber M. E., Fang S. M., Fischer W. H., Jones K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:1998;451-462.
105. Wimmer J., Fujinaga K., Taube R., Cujec T. P., Zhu Y., Peng J., Price D. H., Peterlin B. M. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology. 255:1999;182-189.
106. Wu-Baer F., Lane W. S., Gaynor R. B. Role of the human homolog of the yeast transcription factor SPT5 in HIV-1 Tat-activation. J. Mol. Biol. 277:1998;179-197.
107. Yamaguchi Y., Takagi T., Wada T., Yano K., Furuya A., Sugimoto S., Hasegawa J., Handa H. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell. 97:1999;41-51.
108. Yamaguchi Y., Wada T., Handa H. Interplay between positive and negative elongation factors: Drawing a new view of DRB. Genes Cells. 3:1998;9-15.
109. Yang X., Herrmann C. H., Rice A. P. The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J. Virol. 70:1996;4576-4584.
110. Zawel L., Kumar K. P., Reinberg D. Recycling of the general transcription factors during RNA polymerase II transcription. Genes Dev. 9:1995;1479-1490.
111. Zawel L., Reinberg D. Common themes in assembly and function of eukaryotic transcription complexes. Annu. Rev. Biochem. 64:1995;533-561.
112. Zhu Y., Pe'ery T., Peng J., Ramanathan Y., Marshall N., Marshall T., Amendt B., Mathews M. B., Price D. H. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11:1997;2622-2632.